文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

通过荧光共振能量转移成像评估含前列腺特异性膜抗原(PSMA)的内体的还原电位。

Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging.

作者信息

Venkatesh Chelvam, Shen Jiayin, Putt Karson S, Low Philip S

机构信息

Discipline of Chemistry, Indian Institute of Technology, Madhya Pradesh, Indore 453552, India.

Discipline of Bioscience and Biomedical Engineering, Indian Institute of Technology, Madhya Pradesh, Indore 453552, India.

出版信息

Cancer Drug Resist. 2021 Mar 19;4(1):223-232. doi: 10.20517/cdr.2020.84. eCollection 2021.


DOI:10.20517/cdr.2020.84
PMID:35582012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9019189/
Abstract

: Ligand-targeted therapeutics are experiencing increasing use for treatment of human diseases due to their ability to concentrate a desired drug at a pathologic site while reducing accumulation in healthy tissues. For many ligand-targeted drug conjugates, a critical aspect of conjugate design lies in engineering release of the therapeutic payload to occur only after its internalization by targeted cells. Because disulfide bond reduction is frequently exploited to ensure intracellular drug release, an understanding of the redox properties of endocytic compartments can be critical to ligand-targeted drug design. While the redox properties of folate receptor trafficking endosomes have been previously reported, little is known about the trafficking of prostate-specific membrane antigen (PSMA), a receptor that is experiencing increasing use for drug targeting in humans. : To obtain this information, we have constructed a PSMA-targeted fluorescence resonance energy transfer pair that reports on disulfide bond reduction by changing fluorescence from red to green. : We show here that this reporter exhibits rapid and selective uptake by PSMA-positive cells, and that reduction of its disulfide bond proceeds steadily but incompletely following internalization. The fact that maximal disulfide reduction reaches only ~50%, even after 24 h incubation, suggests that roughly half of the conjugates must traffic through endosomes that display no reducing capacity. : As the level of disulfide reduction differs between PSMA trafficked and previously published folate trafficked conjugates, it also follows that not all internalizing receptors are translocated through similar intracellular compartments. Taken together, these data suggest that the efficiency of disulfide bond reduction must be independently analyzed for each receptor trafficking pathway when disulfide bond reduction is exploited for intracellular drug release.

摘要

由于能够将所需药物集中在病理部位,同时减少在健康组织中的积累,配体靶向疗法在人类疾病治疗中的应用越来越广泛。对于许多配体靶向药物偶联物而言,偶联物设计的一个关键方面在于设计治疗性有效载荷的释放,使其仅在被靶向细胞内化后才发生。由于二硫键还原常被用于确保细胞内药物释放,因此了解内吞小室的氧化还原特性对于配体靶向药物设计至关重要。虽然先前已报道了叶酸受体转运内体的氧化还原特性,但对于前列腺特异性膜抗原(PSMA)的转运了解甚少,PSMA是一种在人类药物靶向中应用越来越广泛的受体。

为了获得这些信息,我们构建了一个PSMA靶向的荧光共振能量转移对,通过将荧光从红色变为绿色来报告二硫键的还原情况。

我们在此表明,该报告分子在PSMA阳性细胞中表现出快速且选择性的摄取,并且其二硫键在内化后稳定但不完全地进行还原。即使在孵育24小时后,最大二硫键还原仅达到约50%,这一事实表明大约一半的偶联物必须通过没有还原能力的内体进行转运。

由于PSMA转运的偶联物与先前发表的叶酸转运的偶联物之间二硫键还原水平不同,因此也可以得出结论,并非所有内化受体都通过相似的细胞内区室进行转运。综上所述,这些数据表明,当利用二硫键还原进行细胞内药物释放时,必须针对每个受体转运途径独立分析二硫键还原的效率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/15ea47818aae/cdr-4-223.fig.4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/efd185ab5b65/cdr-4-223.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/d8d92c4cfab5/cdr-4-223.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/ffbc7aabfde9/cdr-4-223.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/15ea47818aae/cdr-4-223.fig.4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/efd185ab5b65/cdr-4-223.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/d8d92c4cfab5/cdr-4-223.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/ffbc7aabfde9/cdr-4-223.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/15ea47818aae/cdr-4-223.fig.4.jpg

相似文献

[1]
Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging.

Cancer Drug Resist. 2021-3-19

[2]
Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.

Proc Natl Acad Sci U S A. 2006-9-12

[3]
Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.

Proc Natl Acad Sci U S A. 2005-12-13

[4]
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.

Mol Pharm. 2018-4-5

[5]
Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates.

J Pharmacol Exp Ther. 2007-5

[6]
Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.

Mol Pharm. 2012-1-9

[7]
Development of a Cysteine-Conjugatable Disulfide FRET Probe: Influence of Charge on Linker Cleavage and Payload Trafficking for an Anti-HER2 Antibody Conjugate.

Bioconjug Chem. 2019-12-3

[8]
Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells.

Mol Pharm. 2009

[9]
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.

Mol Pharm. 2009

[10]
Tagging Transferrin Receptor with a Disulfide FRET Probe To Gauge the Redox State in Endosomal Compartments.

Anal Chem. 2020-9-15

引用本文的文献

[1]
Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent.

Mol Ther Nucleic Acids. 2024-4-23

[2]
Recent advances in tumor-targeting chemotherapy drugs.

Cancer Drug Resist. 2021

本文引用的文献

[1]
Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC).

Cancers (Basel). 2019-9-3

[2]
Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.

Bioconjug Chem. 2019-5-22

[3]
Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.

Med Res Rev. 2018-5-17

[4]
Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).

Nanomedicine. 2018-4-19

[5]
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.

Mol Pharm. 2018-4-5

[6]
Intraindividual Comparison of F-PSMA-1007 and F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.

J Nucl Med. 2017-12-21

[7]
Ligand-Targeted Drug Delivery.

Chem Rev. 2017-9-12

[8]
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

J Nucl Med. 2016-8

[9]
Endocytic pathways and endosomal trafficking: a primer.

Wien Med Wochenschr. 2016-5

[10]
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.

Clin Cancer Res. 2016-2-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索